Aberrant responses of human lymphocytic neoplasms to cytokine regulation.

P C Nowell, J S Moore
Author Information
  1. P C Nowell: Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, USA. nowell@mail.med.upenn.edu

Abstract

Studies in this laboratory have recently focused on two hemic neoplasms: B cell chronic lymphocytic leukemia (B-CLL) and a T cell disorder, Sézary syndrome. These tumors do not have consistent cytogenetic or molecular genetic alterations, and so we have concentrated on their response to and production of various regulatory cytokines. Although B-CLL cells show variable proliferative responses when exposed to transforming growth factor beta (TGF beta), these cells have consistently shown resistance to the pro-apoptotic effects of this cytokine. Also, interleukin 4 (IL4), IL5, and interferon-gamma (IFN gamma) all show a consistently increased protective effect against apoptosis in B-CLL cells as compared to normal human B cells. Thus, a defect in apoptosis appears to be an important factor in the pathogenesis of CLL. By contrast, the neoplastic T cells of Sézary syndrome show a consistent resistance to the antiproliferative effects of TGF beta, suggesting that aberrant proliferation is more important than apoptosis in this disorder. In both neoplasms, we have shown that the defective responses to cytokines are in some instances related to alterations in receptor expression, but this has not been true in all circumstances, and other stages in the signaling pathways are being investigated. As we define more precisely the specific defects that contribute to the clonal expansion of these neoplasms, the findings may ultimately lead to improved clinical control of these disorders.

References

  1. Blood. 1997 Feb 1;89(3):941-7 [PMID: 9028325]
  2. J Immunol. 1988 May 1;140(9):3026-32 [PMID: 3129508]
  3. J Exp Med. 1992 Nov 1;176(5):1319-26 [PMID: 1402678]
  4. J Immunol. 1997 May 15;158(10):4984-91 [PMID: 9144518]
  5. J Invest Dermatol. 1989 Sep;93(3):413-6 [PMID: 2527911]
  6. Blood. 1997 May 15;89(10):3817-25 [PMID: 9160689]
  7. Proc Natl Acad Sci U S A. 1997 May 27;94(11):5877-81 [PMID: 9159168]
  8. Blood. 1996 Apr 15;87(8):3327-35 [PMID: 8605349]
  9. J Immunol. 1986 Dec 15;137(12):3855-60 [PMID: 2878044]
  10. Br J Haematol. 1993 Nov;85(3):439-45 [PMID: 8136263]
  11. Blood. 1997 May 1;89(9):3371-7 [PMID: 9129044]
  12. J Immunol. 1995 Feb 1;154(3):1491-8 [PMID: 7822812]
  13. Br J Haematol. 1996 Mar;92 (4):890-9 [PMID: 8616082]
  14. Cancer Res. 1995 Dec 1;55(23):5545-7 [PMID: 7585631]
  15. Proc Natl Acad Sci U S A. 1996 Aug 20;93(17 ):9148-53 [PMID: 8799169]
  16. Cell Immunol. 1997 Aug 1;179(2):126-37 [PMID: 9268496]
  17. J Immunol. 1993 Dec 15;151(12):7273-83 [PMID: 7505024]
  18. Cell. 1991 Nov 15;67(4):641-4 [PMID: 1934065]
  19. Oncogene. 1995 Oct 19;11(8):1615-22 [PMID: 7478586]
  20. Arch Dermatol. 1994 Feb;130(2):198-203 [PMID: 8304758]
  21. Ann N Y Acad Sci. 1992 May 4;651:488-90 [PMID: 1376068]
  22. Cancer Genet Cytogenet. 1997 Mar;94(1):13-9 [PMID: 9078286]
  23. J Exp Med. 1994 Mar 1;179(3):999-1004 [PMID: 8113691]
  24. J Exp Med. 1993 Jan 1;177(1):213-8 [PMID: 7678114]
  25. Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6002-6 [PMID: 8016105]
  26. Blood. 1997 May 1;89(9):3378-84 [PMID: 9129045]
  27. Br J Haematol. 1992 Apr;80(4):480-7 [PMID: 1581232]
  28. Cancer Res. 1992 Jan 15;52(2):437-43 [PMID: 1370214]
  29. J Exp Med. 1997 Mar 17;185(6):1035-42 [PMID: 9091577]
  30. J Immunol. 1988 Dec 15;141(12):4133-9 [PMID: 3264305]
  31. Blood. 1997 Apr 15;89(8):2833-41 [PMID: 9108402]
  32. Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5501-5 [PMID: 7777538]
  33. J Am Acad Dermatol. 1980 Feb;2(2):89-106 [PMID: 6988470]
  34. Am J Clin Pathol. 1996 Dec;106(6):739-48 [PMID: 8980349]
  35. Crit Rev Oncol Hematol. 1995 Aug;20(1-2):141-64 [PMID: 7576195]

MeSH Term

Apoptosis
Cytokines
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
Sezary Syndrome

Chemicals

Cytokines

Word Cloud

Created with Highcharts 10.0.0cellsB-CLLshowresponsesbetaapoptosisneoplasmsBcelllymphocyticTdisorderSézarysyndromeconsistentalterationscytokinesfactorTGFconsistentlyshownresistanceeffectscytokinehumanimportantStudieslaboratoryrecentlyfocusedtwohemicneoplasms:chronicleukemiatumorscytogeneticmoleculargeneticconcentratedresponseproductionvariousregulatoryAlthoughvariableproliferativeexposedtransforminggrowthpro-apoptoticAlsointerleukin4IL4IL5interferon-gammaIFNgammaincreasedprotectiveeffectcomparednormalThusdefectappearspathogenesisCLLcontrastneoplasticantiproliferativesuggestingaberrantproliferationdefectiveinstancesrelatedreceptorexpressiontruecircumstancesstagessignalingpathwaysinvestigateddefinepreciselyspecificdefectscontributeclonalexpansionfindingsmayultimatelyleadimprovedclinicalcontroldisordersAberrantregulation

Similar Articles

Cited By